337 related articles for article (PubMed ID: 25233397)
1. PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer.
Papadaki C; Sfakianaki M; Lagoudaki E; Giagkas G; Ioannidis G; Trypaki M; Tsakalaki E; Voutsina A; Koutsopoulos A; Mavroudis D; Georgoulias V; Souglakos J
Br J Cancer; 2014 Oct; 111(9):1757-64. PubMed ID: 25233397
[TBL] [Abstract][Full Text] [Related]
2. Associations between TS, TTF-1, FR-α, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy.
Grønberg BH; Lund-Iversen M; Strøm EH; Brustugun OT; Scott H
J Thorac Oncol; 2013 Oct; 8(10):1255-64. PubMed ID: 24457236
[TBL] [Abstract][Full Text] [Related]
3. ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
Ozdemir O; Ozdemir P; Veral A; Uluer H; Ozhan MH
Asian Pac J Cancer Prev; 2013; 14(8):4679-83. PubMed ID: 24083725
[TBL] [Abstract][Full Text] [Related]
4. Pyruvate Kinase M2 Modulates Esophageal Squamous Cell Carcinoma Chemotherapy Response by Regulating the Pentose Phosphate Pathway.
Fukuda S; Miyata H; Miyazaki Y; Makino T; Takahashi T; Kurokawa Y; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1461-8. PubMed ID: 25808097
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial.
Gridelli C; Bennouna J; de Castro J; Dingemans AM; Griesinger F; Grossi F; Rossi A; Thatcher N; Wong EK; Langer C
Clin Lung Cancer; 2011 Nov; 12(6):407-11. PubMed ID: 21705281
[TBL] [Abstract][Full Text] [Related]
6. Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients.
Peng Y; Li Z; Zhang S; Xiong Y; Cun Y; Qian C; Li M; Ren T; Xia L; Cheng Y; Wang D
Int J Cancer; 2014 Dec; 135(11):2687-96. PubMed ID: 24729390
[TBL] [Abstract][Full Text] [Related]
7. Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.
Zhang X; Lu J; Xu J; Li H; Wang J; Qin Y; Ma P; Wei L; He J
Respirology; 2013 Jan; 18(1):131-9. PubMed ID: 22882698
[TBL] [Abstract][Full Text] [Related]
8. Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial.
Nicolson MC; Fennell DA; Ferry D; O'Byrne K; Shah R; Potter V; Skailes G; Upadhyay S; Taylor P; André V; Nguyen TS; Myrand SP; Visseren-Grul C; Das M; Kerr KM
J Thorac Oncol; 2013 Jul; 8(7):930-9. PubMed ID: 23722170
[TBL] [Abstract][Full Text] [Related]
9. Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer.
Li CH; Liu MY; Liu W; Li DD; Cai L
Asian Pac J Cancer Prev; 2014; 15(2):731-6. PubMed ID: 24568487
[TBL] [Abstract][Full Text] [Related]
10. Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancer.
Gridelli C; Rossi A; Di Maio M; Leo S; Filipazzi V; Favaretto AG; Burgio MA; Cinieri S; Bianco R; Ciardiello F; Cavanna L; Bordonaro R; Costanzo R; Sandomenico C; Gallo C; Perrone F; Morabito A
Clin Lung Cancer; 2014 Mar; 15(2):166-70. PubMed ID: 24418693
[TBL] [Abstract][Full Text] [Related]
11. Advanced non-small cell lung cancer (NSCLC): maintenance therapy for all?
Hashemi-Sadraei N; Pennell NA
Curr Treat Options Oncol; 2012 Dec; 13(4):478-90. PubMed ID: 22972369
[TBL] [Abstract][Full Text] [Related]
12. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions.
Ramalingam S; Belani C
Oncologist; 2008; 13 Suppl 1():5-13. PubMed ID: 18263769
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer.
Bepler G; Sommers KE; Cantor A; Li X; Sharma A; Williams C; Chiappori A; Haura E; Antonia S; Tanvetyanon T; Simon G; Obasaju C; Robinson LA
J Thorac Oncol; 2008 Oct; 3(10):1112-8. PubMed ID: 18827606
[TBL] [Abstract][Full Text] [Related]
14. First-line platinum-based chemotherapy and survival outcomes in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma.
Lin Z; Fu S; Zhou Y; Zhang X; Chen C; He LN; Li H; Wang Y; Chen T; Zhang L; Hong S
Lung Cancer; 2019 Nov; 137():100-107. PubMed ID: 31568886
[TBL] [Abstract][Full Text] [Related]
15. Patients treated with platinum-doublet chemotherapy for advanced non--small-cell lung cancer have inferior outcomes if previously treated with platinum-based chemoradiation.
Paramanathan A; Solomon B; Collins M; Franco M; Kofoed S; Francis H; Ball D; Mileshkin L
Clin Lung Cancer; 2013 Sep; 14(5):508-12. PubMed ID: 23792009
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma.
Vieira T; Girard N; Ung M; Monnet I; Cazes A; Bonnette P; Duruisseaux M; Mazieres J; Antoine M; Cadranel J; Wislez M
J Thorac Oncol; 2013 Dec; 8(12):1574-7. PubMed ID: 24389441
[TBL] [Abstract][Full Text] [Related]
17. Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.
Joerger M; deJong D; Burylo A; Burgers JA; Baas P; Huitema AD; Beijnen JH; Schellens JH
Lung Cancer; 2011 Nov; 74(2):310-7. PubMed ID: 21529986
[TBL] [Abstract][Full Text] [Related]
18. Perspectives on salvage therapy for non-small-cell lung cancer.
Cappuzzo F; Finocchiaro G; Trisolini R; Toschi L; Bartolini S; Metro G; Crinò L
Oncology (Williston Park); 2005 Jul; 19(8):989-95; discussion 995-6, 999, 1003-4, passim. PubMed ID: 16131043
[TBL] [Abstract][Full Text] [Related]
19. High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.
Ren S; Zhou S; Zhang L; Xu J; Lv M; Zhang J; Zhou C; Zhang J
Cancer Invest; 2010 Dec; 28(10):1078-83. PubMed ID: 20504223
[TBL] [Abstract][Full Text] [Related]
20. Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice.
Girard N; Jacoulet P; Gainet M; Elleuch R; Pernet D; Depierre A; Dalphin JC; Westeel V
J Thorac Oncol; 2009 Dec; 4(12):1544-9. PubMed ID: 19884862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
